Denali Therapeutics Inc.
NASDAQ: DNLI0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ryan J. Watts
- Employees
- 443
- Headquarters
- South San Francisco, United States
- IPO year
- 2017
- Market cap
- $3.7B
- Website
- https://www.denalitherapeutics.com
Loading DNLI…
Loading profile data…Frequently asked questions about DNLI
What does Denali Therapeutics Inc. (DNLI) do?
Denali Therapeutics Inc. is a biopharmaceutical firm, founded in 2013 and based in South San Francisco, California, which focuses on identifying and advancing treatments for neurodegenerative conditions within the United States. The company, initially known as SPR Pharma Inc. until its renaming in March 2015, possesses a robust development pipel...
Where does DNLI trade?
Denali Therapeutics Inc. (DNLI) trades on the NASDAQ Global Select.
What sector is DNLI in?
Denali Therapeutics Inc. (DNLI) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Denali Therapeutics Inc.?
Ryan J. Watts is the chief executive officer of Denali Therapeutics Inc. (DNLI).
Where is Denali Therapeutics Inc. headquartered?
Denali Therapeutics Inc. is headquartered in United States.
Does DNLI pay a dividend?
Denali Therapeutics Inc. (DNLI) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did DNLI go public?
Denali Therapeutics Inc. (DNLI) completed its initial public offering in 2017.